 Steven Johnson
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 16 | 2024 | 2744 | 1.780 |
Why?
| | Vaccination | 2 | 2024 | 1362 | 0.880 |
Why?
| | Q Fever | 1 | 2019 | 5 | 0.680 |
Why?
| | Anti-Retroviral Agents | 3 | 2016 | 230 | 0.650 |
Why?
| | Endocarditis, Bacterial | 1 | 2019 | 43 | 0.640 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 112 | 0.610 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2019 | 269 | 0.590 |
Why?
| | 6-Phytase | 3 | 2012 | 3 | 0.520 |
Why?
| | Lilium | 3 | 2012 | 3 | 0.520 |
Why?
| | Drug Monitoring | 2 | 2016 | 193 | 0.510 |
Why?
| | Pichia | 2 | 2012 | 22 | 0.450 |
Why?
| | Kidney Transplantation | 1 | 2019 | 638 | 0.420 |
Why?
| | Fasciola hepatica | 1 | 2012 | 5 | 0.390 |
Why?
| | Topography, Medical | 1 | 2012 | 12 | 0.390 |
Why?
| | Fascioliasis | 1 | 2012 | 7 | 0.390 |
Why?
| | Residence Characteristics | 1 | 2013 | 327 | 0.350 |
Why?
| | Lasers, Excimer | 1 | 2010 | 29 | 0.330 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2010 | 22 | 0.330 |
Why?
| | Myopia | 1 | 2010 | 48 | 0.320 |
Why?
| | Sexual Behavior | 1 | 2013 | 483 | 0.310 |
Why?
| | Intraoperative Complications | 1 | 2010 | 133 | 0.310 |
Why?
| | Surgical Flaps | 1 | 2010 | 140 | 0.300 |
Why?
| | Transplant Recipients | 2 | 2020 | 157 | 0.300 |
Why?
| | Antiviral Agents | 3 | 2020 | 709 | 0.270 |
Why?
| | Middle Aged | 13 | 2021 | 31103 | 0.200 |
Why?
| | Prisons | 2 | 2020 | 83 | 0.200 |
Why?
| | Humans | 25 | 2024 | 129705 | 0.190 |
Why?
| | HIV-1 | 4 | 2021 | 841 | 0.180 |
Why?
| | Telemedicine | 2 | 2020 | 792 | 0.180 |
Why?
| | Hepatitis A | 1 | 2020 | 26 | 0.180 |
Why?
| | New York | 1 | 2020 | 127 | 0.170 |
Why?
| | Hepatitis B Vaccines | 1 | 2020 | 49 | 0.170 |
Why?
| | Meningococcal Vaccines | 1 | 2020 | 54 | 0.170 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.170 |
Why?
| | Patient Compliance | 3 | 2014 | 566 | 0.170 |
Why?
| | Advance Directives | 1 | 2021 | 79 | 0.170 |
Why?
| | Kidney | 2 | 2019 | 1330 | 0.160 |
Why?
| | Advisory Committees | 1 | 2020 | 231 | 0.160 |
Why?
| | Myocarditis | 1 | 2020 | 101 | 0.160 |
Why?
| | Pollen | 2 | 2010 | 25 | 0.150 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2019 | 227 | 0.150 |
Why?
| | Cytomegalovirus Infections | 1 | 2020 | 194 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2020 | 150 | 0.150 |
Why?
| | RNA, Viral | 2 | 2020 | 622 | 0.140 |
Why?
| | Papillomavirus Vaccines | 1 | 2020 | 229 | 0.140 |
Why?
| | Advance Care Planning | 1 | 2021 | 206 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.140 |
Why?
| | Prisoners | 1 | 2019 | 144 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2020 | 226 | 0.140 |
Why?
| | Time Factors | 4 | 2020 | 6593 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 474 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2020 | 607 | 0.130 |
Why?
| | Adult | 11 | 2021 | 35595 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 361 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 355 | 0.120 |
Why?
| | Viral Load | 2 | 2014 | 449 | 0.110 |
Why?
| | Decision Making | 1 | 2021 | 842 | 0.110 |
Why?
| | Female | 12 | 2021 | 68561 | 0.110 |
Why?
| | Comorbidity | 2 | 2019 | 1545 | 0.100 |
Why?
| | Phosphorous Acids | 1 | 2012 | 13 | 0.100 |
Why?
| | Phytic Acid | 2 | 2010 | 43 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 502 | 0.100 |
Why?
| | Male | 14 | 2021 | 63544 | 0.100 |
Why?
| | United States | 5 | 2020 | 14078 | 0.100 |
Why?
| | Refugees | 1 | 2013 | 66 | 0.100 |
Why?
| | Life Cycle Stages | 1 | 2012 | 34 | 0.100 |
Why?
| | Africa | 1 | 2012 | 102 | 0.100 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 279 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1526 | 0.090 |
Why?
| | Mass Screening | 3 | 2020 | 1130 | 0.090 |
Why?
| | Aged | 4 | 2021 | 22113 | 0.090 |
Why?
| | Cloning, Molecular | 1 | 2012 | 536 | 0.090 |
Why?
| | Aging | 1 | 2021 | 1769 | 0.090 |
Why?
| | Travel | 1 | 2012 | 123 | 0.090 |
Why?
| | Primary Health Care | 1 | 2021 | 1668 | 0.090 |
Why?
| | Adenine | 1 | 2012 | 247 | 0.090 |
Why?
| | Botulinum Toxins, Type A | 1 | 2010 | 40 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2011 | 93 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2539 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1719 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2021 | 14669 | 0.080 |
Why?
| | Genetic Vectors | 1 | 2010 | 315 | 0.080 |
Why?
| | Colorado | 5 | 2020 | 4471 | 0.080 |
Why?
| | Protein Folding | 1 | 2010 | 261 | 0.080 |
Why?
| | Drug Prescriptions | 1 | 2011 | 254 | 0.080 |
Why?
| | Anti-HIV Agents | 2 | 2012 | 744 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 640 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 328 | 0.070 |
Why?
| | Risk Factors | 3 | 2021 | 9832 | 0.070 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2006 | 54 | 0.060 |
Why?
| | CD4 Lymphocyte Count | 3 | 2014 | 269 | 0.060 |
Why?
| | Age Factors | 1 | 2013 | 3145 | 0.060 |
Why?
| | Prospective Studies | 3 | 2019 | 7130 | 0.060 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2005 | 11 | 0.060 |
Why?
| | Lamivudine | 1 | 2005 | 61 | 0.060 |
Why?
| | Delivery of Health Care | 3 | 2019 | 904 | 0.060 |
Why?
| | Substance-Related Disorders | 1 | 2013 | 1023 | 0.060 |
Why?
| | Salvage Therapy | 1 | 2005 | 136 | 0.060 |
Why?
| | Medication Adherence | 1 | 2009 | 576 | 0.060 |
Why?
| | Incidence | 1 | 2010 | 2658 | 0.050 |
Why?
| | Neurons | 1 | 2010 | 1428 | 0.050 |
Why?
| | Disease Progression | 1 | 2009 | 2612 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2020 | 26 | 0.040 |
Why?
| | Coinfection | 1 | 2021 | 133 | 0.040 |
Why?
| | Quarantine | 1 | 2020 | 28 | 0.040 |
Why?
| | Drug Users | 1 | 2020 | 44 | 0.040 |
Why?
| | Death | 1 | 2021 | 125 | 0.040 |
Why?
| | Immunoassay | 1 | 2020 | 104 | 0.040 |
Why?
| | Proteinuria | 1 | 2020 | 89 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 121 | 0.040 |
Why?
| | Animals | 4 | 2021 | 34733 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2010 | 2044 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 962 | 0.040 |
Why?
| | Cause of Death | 1 | 2019 | 394 | 0.040 |
Why?
| | Risk-Taking | 1 | 2020 | 361 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 349 | 0.030 |
Why?
| | Young Adult | 2 | 2011 | 12363 | 0.030 |
Why?
| | Base Sequence | 2 | 2012 | 2161 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2012 | 2051 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1442 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2012 | 2848 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1721 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1567 | 0.030 |
Why?
| | Prevalence | 1 | 2020 | 2557 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 22 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2020 | 908 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 917 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 828 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2091 | 0.020 |
Why?
| | Gene Dosage | 1 | 2012 | 143 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2012 | 333 | 0.020 |
Why?
| | Plasmids | 1 | 2012 | 359 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 434 | 0.020 |
Why?
| | Toes | 1 | 2010 | 27 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 485 | 0.020 |
Why?
| | Hospitals, University | 1 | 2011 | 177 | 0.020 |
Why?
| | Neuromuscular Junction | 1 | 2010 | 56 | 0.020 |
Why?
| | Reflex | 1 | 2010 | 67 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 361 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1212 | 0.020 |
Why?
| | Drug Carriers | 1 | 2010 | 115 | 0.020 |
Why?
| | Protein Engineering | 1 | 2010 | 114 | 0.020 |
Why?
| | Temperature | 1 | 2012 | 634 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 424 | 0.020 |
Why?
| | Informed Consent | 1 | 2010 | 184 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2012 | 1306 | 0.020 |
Why?
| | Public Health | 1 | 2013 | 498 | 0.020 |
Why?
| | Motor Neurons | 1 | 2010 | 236 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 833 | 0.020 |
Why?
| | Urban Population | 1 | 2010 | 442 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1477 | 0.020 |
Why?
| | Escherichia coli | 1 | 2010 | 790 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2006 | 150 | 0.020 |
Why?
| | Histidine | 1 | 2006 | 61 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2006 | 370 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2011 | 731 | 0.020 |
Why?
| | Molecular Structure | 1 | 2006 | 469 | 0.010 |
Why?
| | Neoplasms | 1 | 2019 | 2435 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2006 | 1047 | 0.010 |
Why?
| | Phylogeny | 1 | 2006 | 864 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 10299 | 0.010 |
Why?
| | Rats | 1 | 2006 | 5244 | 0.010 |
Why?
| | Mutation | 1 | 2005 | 3674 | 0.010 |
Why?
| | Mice | 1 | 2010 | 16585 | 0.010 |
Why?
| | Adolescent | 1 | 2011 | 20355 | 0.010 |
Why?
|
|
Johnson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|